Clinical trials: Allergen Immunotherapy
Allergic Rhinitis
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
The objective of this clinical trial is to assess the safety and efficacy of sublingual application of allergen extracts for specific immunotherapy in patients suffering from perennial allergic rhinitis due to house dust mites.
- Trial name
- NCT01014325
- Testing
- Allergen extract
- Where
- Spain
- Volunteers
- 130 people
- Sponsor
- Roxall Medizin
Seasonal Allergic Rhinitis
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen
The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerised with glutaraldehyde)of the subcutaneous injection of Phleum pratense pollen in the treatment of patients affected…
- Trial name
- NCT00916422
- Testing
- Allergen extract (Phleum pratense)
- Where
- 23 sites in Hungary, Spain
- Volunteers
- 153 people
- Sponsor
- Laboratorios Leti, S.L.
Hypersensitivity
Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy
The purpose of this study is to evaluate whether the use of a specific immunomodulatory principle (QbG10) together with conventional grass pollen allergen leads to a more rapid and more pronounced decrease of sensitivity against…
- Trial name
- NCT00293904
- Testing
- CYT005-AllQbG10
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- Cytos Biotechnology AG
Allergy
Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets
A phase III study to evaluate Long term efficacy , carry-over effect and safety of 300 IR sublingual Immunotherapy (SLIT) tablets in adults patients suffering from grass pollen rhinoconjunctivitis
- Trial name
- NCT00418379
- Testing
- 300 IR (4M), 300 IR (2M)
- Where
- France
- Volunteers
- 633 people
- Sponsor
- Stallergenes Greer
Allergy, Rhinoconjunctivitis
Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Olea europaea in the rhinitis or allergic rhinoconjunctivitis
- Trial name
- NCT00537342
- Testing
- Immunotherapy with modified extract of O. europaea pollen
- Where
- Spain
- Volunteers
- 83 people
- Sponsor
- Laboratorios Leti, S.L.
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae
- Trial name
- NOVUS-UP (NCT07096440)
- Volunteers
- 105 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergy to Mites
Biological Standardization of Blomia Tropicalis Allergen Extract
The objective of this study is to determine the biologic activity of a Blomia tropicalis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01597752
- Testing
- Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Laboratorios Leti, S.L.
Allergic Rhinoconjunctivitis
Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative
This trial is performed for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen, rBet v1-FV
- Trial name
- NCT00841516
- Testing
- rBet v1-FV
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergy to Grass Pollen
Biological Standardization of Lolium Perenne Allergen Extract
The objective of this study is to determine the biologic activity of a Lolium perenne allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01394289
- Testing
- Lolium allergen extract
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind placebo-controlled setting
- Trial name
- NCT00574223
- Testing
- CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Cytos Biotechnology AG
Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
The purpose of this study is to determine the proportion of participants that initiate allergen immunotherapy (AIT) upon the recommendation of their physician and the proportion of participants that persist with their AIT…
- Trial name
- NCT01549340
- Volunteers
- 8,790 people
- Sponsor
- ALK-Abelló A/S
Peanut Allergy
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
This is a multi-center, open-label, follow-on study to gather additional information on the safety and tolerability of oral desensitization with CPNA in the subjects who participated in ARC001.
- Trial name
- NCT02198664
- Testing
- AR101 - Peanut protein capsule
- Where
- 8 sites in United States
- Volunteers
- 47 people
- Sponsor
- Aimmune Therapeutics, Inc.
Ragweed Allergy, Rhinoconjunctivitis
ToleroMune Ragweed Follow up Study
Ragweed is the primary cause of autumn allergies. The ragweed season begins in mid-August. In the third National Health and Nutrition Examination Surveys54.3% of the population had positive test responses to one or more…
- Trial name
- NCT01448603
- Testing
- ToleroMune Ragweed
- Where
- Canada
- Volunteers
- 109 people
- Sponsor
- Circassia Limited
Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma, Immunotherapy, Allergen
Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for subcutaneous application: Dose finding study to evaluate the correct dose. 4 concentrations of a birch pollen allergen extract are applied in this study. Duration of therapy 20 weeks.
- Trial name
- NCT01144429
- Testing
- Allergoid, allergenic extract of 100% Birch
- Where
- 39 sites in Germany, Lithuania and 1 more
- Volunteers
- 344 people
- Sponsor
- Leti Pharma GmbH
Allergic Rhinitis, Conjunctivitis
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU)…
- Trial name
- NCT05430919
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 3 sites in Canada
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Allergic Rhinitis, Grass Allergy
Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis
Adherence to treatment is crucial to the efficacy of sublingual immunotherapy of allergic diseases. GRAZAX® is a registered drug in Europe, with established efficacy in the treatment of allergic rhinitis, which has to be taken…
- Trial name
- GT-17 (NCT01728285)
- Testing
- Electronic compliance device (Memozax®)
- Where
- Italy
- Volunteers
- 261 people
- Sponsor
- ALK-Abelló A/S
Allergy to Grass Pollen (Dactylis Glomerata)
Biological Standardization of Dactylis Glomerata Allergen Extract
The objective of this study is to determine the biologic activity of a Dactylis glomerata allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01407835
- Testing
- Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
House Dust Mite Allergy
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis
- Trial name
- NCT00263549
- Testing
- House dust mite Novo Helisen Depot
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinitis, Allergic, Respiratory Tract Infections
Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels
Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their…
- Conditions
- Rhinitis, Allergic, Respiratory Tract Infections, Allergy, Allergic Asthma
- Trial name
- NCT04389034
- Testing
- Pollinex Quattro with tree- and grass pollen extracts and their mixtures
- Where
- Germany
- Volunteers
- 113 people
- Sponsor
- Allergy Therapeutics
Rhinoconjunctivitis, Rhinitis
Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00562159
- Testing
- SCH 697243, Loratadine 10 mg Rescue Treatment, Olopatadine 0.1% Rescue Treatment
- Volunteers
- 439 people
- Sponsor
- ALK-Abelló A/S